Skip to main content
. 2021 Dec 13;82(4):708–720. doi: 10.1158/0008-5472.CAN-21-1222

Figure 4.

Figure 4. Trabectedin impairs the HMGA2/IGF2BP2–3/IGF network and inhibits AKT pathway activity in combination with NVP-BEZ235 treatment. A and B, qRT-PCR analysis of HMGA2/IGF2BP2–3 mRNA expression (A) and Western blot analysis of HMGA2/IGF2BP2–3/IGF2/IGF1R protein expression (B) in PDX-CDS#4-C and PDX-CDS#3-C cells treated with 3 nmol/L trabectedin for the indicated time. At least three independent biological replicates were performed. One representative immunoblot is shown. For qRT-PCR, the data represent the mean ± SE. *, P < 0.05; **, P < 0.01; ****, P < 0.0001, one-way ANOVA. Each dot represents an independent experiment. GAPDH was used as a reference gene. C, Western blot analysis showing activation of IGF1R and the downstream mediator AKT in PDX-CDS#4-C and PDX-CDS#3-C cells treated with 3 nmol/L trabectedin for 24 hours with or without a subsequent 24 hours treatment with different doses of NVP-BEZ235. Three independent biological replicates were performed. One representative immunoblot is shown. GAPDH was employed for normalization purposes.

Trabectedin impairs the HMGA2/IGF2BP2–3/IGF network and inhibits AKT pathway activity in combination with NVP-BEZ235 treatment. A and B, qRT-PCR analysis of HMGA2/IGF2BP2–3 mRNA expression (A) and Western blot analysis of HMGA2/IGF2BP2–3/IGF2/IGF1R protein expression (B) in PDX-CDS#4-C and PDX-CDS#3-C cells treated with 3 nmol/L trabectedin for the indicated time. At least three independent biological replicates were performed. One representative immunoblot is shown. For qRT-PCR, the data represent the mean ± SE. *, P < 0.05; **, P < 0.01; ****, P < 0.0001, one-way ANOVA. Each dot represents an independent experiment. GAPDH was used as a reference gene. C, Western blot analysis showing activation of IGF1R and the downstream mediator AKT in PDX-CDS#4-C and PDX-CDS#3-C cells treated with 3 nmol/L trabectedin for 24 hours with or without a subsequent 24 hours treatment with different doses of NVP-BEZ235. Three independent biological replicates were performed. One representative immunoblot is shown. GAPDH was employed for normalization purposes.